AstraZenecaAZN
Recorded

AstraZeneca Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration1 hr 34 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Dave FredricksonEVP of Oncology Business

Good evening and good day to everybody joining us remotely. Thank you for being here with us at our ESMO 2026 Investor Event. My name's Dave Fredrickson. I am the EVP of our oncology business, and it is wonderful to have you here. Here is the agenda that we are going to go through for the day, or the evening, over the next couple of hours. We are very privileged to have two esteemed guests with us. To kick things off, we have Professor Tom Powles, who is on the end of the podium and will be walking us through exciting data in bladder cancer from this year's ESMO. Professor Yi-Long Wu, next to Professor Powles, also joining us with an opportunity to talk through the exciting EGFR lung data that we also saw here and that was presented.

Dave FredricksonEVP of Oncology Business

After that, we will have an opportunity to hear from Leora, Susan, and myself, who will go through the rest of the data that were presented. I will put it into a commercial context. Finally, Pascal is going to have an opportunity to come up before we go into the Q&A and put this oncology data into a broader enterprise context, which we thought would be useful to be able to do. I will note that we will take a Q&A session after Professor Powles gives his presentation. He does need to leave to go to another engagement, so we decided that we would take a moment to be able to give you an opportunity to ask him some questions before he departs. Professor Wu is also going to have to leave after his presentation. Just to set expectations on that.

Dave FredricksonEVP of Oncology Business

If we could go to the next slide, please. What an exciting ESMO it has been for us. When we take a look at ESMO in general, certainly we are energized with the progress the field is making in transforming cancer care. We are also really proud that we are at the vanguard of really leading many of those key trends that are coming through. You see that with four presidential data sets at ESMO, delivering overall survival, showing that we are in fact delivering on some of the core elements that we believe are essential, replacing classic chemotherapy with ADCs, finding new ways to harness the immune system, delivering combinations, and doing that earlier in earlier stages where we think that we can get long-term durable responses. We had data that spanned 27 approved and potential medicines across greater than 15 tumor types.

Dave FredricksonEVP of Oncology Business

You can see an unprecedented number of abstract acceptances that we had, 38 oral presentations, nothing short of remarkable. It is a good opportunity to thank our AstraZeneca teams for all the work that they do in order to make a meeting like this possible. With that, and without further ado, I am going to introduce Professor Thomas Powles.

Thomas PowlesProfessor

Thank you. This is my last talk of the meeting.

Thomas PowlesProfessor

I am super excited, I have got to tell you. Thanks for asking me. I really appreciate it. Also, thanks for involving me in the study. The study has been going on for a long period of time, and we are curing bladder cancer. I think we are doing that, and it is enormously exciting to be part of that journey. The journey is not yet complete. There are other things we need to do. This trial is an important step of that journey because what it tells us is we can give shorter periods of ADC therapy. We have, when we did the first trial, and I was involved in the first trial, we kind of gave ADCs forever because we felt we couldn't beat standard chemotherapy because no one has done it before.

Thomas PowlesProfessor

We entered into this journey with good intentions, and we are now finding these drugs are super active together, and I am excited to talk to you about that. This study goes back a long way. It goes back pre-pandemic, when we designed the trial. The trial was designed with two very specific questions in mind. I am going to focus on one of those two questions today, but I am very happy to answer questions about the other question. The first question that we asked was, in muscle-invasive bladder cancer, these patients historically do really poorly. Until a year ago, these patients were getting cystectomy alone. EV pembro has superseded that with nine perioperative cycles with an operation. It is a huge operation in the middle, and it is not without its challenges because of that.

Thomas PowlesProfessor

The question we asked, which is very different from that, is can we just give this short, sharp period of neoadjuvant therapy three cycles? Very brave in some respects, and I thank people on the panel for supporting that decision. Because when we started, most people felt one would need more treatment than that. The second arm, we thought, let us try and ask a second question at the same time. Let us try and escalate the intensity with CTLA-4 inhibition. I have been a fan of CTLA-4 inhibition in this disease, and that arm is actually ongoing. As I said before, happy to answer questions around it. The control arm, absolutely standard, and completed before EV pembro became available and was also the same control as previous trials in this particular space. It is important to note that this is a study looking at cisplatin-ineligible patients, but also cisplatin-refusing patients.

Thomas PowlesProfessor

It is not uncommon for patients to refuse cisplatin chemotherapy. The drugs aren't great. The benefit overall is relatively modest. Actually, when you look at the global community, and indeed, if you go to countries like Germany, they don't give neoadjuvant chemotherapy at all. So, very justified control arm. When we look at the primary endpoint of the study, I think it is fair to say that while the study had about 230 patients in each arm, it was really balanced in terms of the characteristics of these two arms, and 25% of those patients were refusing, 75% of patients were cisplatin ineligible. The curves go apart, and they stay apart. The median follow-up is 23 months. The statistical analysis plan was event-free survival in both arms with dual primary endpoints, and we then converged to do sequential overall survival.

Thomas PowlesProfessor

This was the first interim analysis of this data with 23 months of follow-up. Again, it was ambitious, but we were quietly confident that because of the EV pembro results being so impressive, that we felt these results would be impressive as well, and indeed they were. The hazard ratio, 0.51. The OS is also impressive, clinically meaningful at 0.58. The curves go apart and they stay apart. The landmark at 78% at 2 years is a really strong data point. When one goes back in time and look at previous studies involving this population, you can see that actually our control arm in this study actually performed quite well.

Thomas PowlesProfessor

That I think is a neat endpoint, and of course it leads on to a forest plot, which inevitably with those very low hazard ratios, although the confidence intervals become wider, which you'll all be familiar with, show a benefit for the EV and the durvalumab combination. EV-D was associated with a higher pCR rate. This was investigator-assessed pCR, which was measured at 45%, and we were lucky enough to get ctDNA analysis. We performed a whole genome rather than exome ctDNA analysis. This is a more accurate, more sensitive test. In this study, we picked up 78% of patients being positive at baseline. In NIAGARA, a previous trial where we used a less sensitive test, we only showed 58% of patients were ctDNA positive. That increased sensitivity is an indication of the field moving forward.

Thomas PowlesProfessor

You'll be aware that the Signatera assay is approved in the U.S., and actually even at my hospital in the U.K., we're using ctDNA at the moment. This is something that's going to be real, and I think ctDNA will supersede other surrogate-type endpoints, particularly in this space. I think this data's important. The 60% clearance is meaningful. Those patients do better. Obviously, the negative patients do about the same that remain negative. I was really pleased we were able to do this. The toxicity profile I think is also important. You'll see here that 30% of patients getting Grade 3 or 4 adverse events, 11% of patients having immune-related toxicity, and 11% of patients having disruption of that enfortumab vedotin neoadjuvantly. I think it's really important personally that we are able to deliver that period of neoadjuvant therapy efficiently.

Thomas PowlesProfessor

Clearly, if you have toxicity problems and other issues, then that can actually affect your initial intensity and potentially compromise outcomes. The adverse event profile was in line with expectations, particularly most of it dominated actually by urology issues. The cystectomy drives a lot of these treatment emergent adverse events. If you focus on treatment-related adverse events, nothing new or unexpected. Actually, a higher proportion of patients got surgery in the neoadjuvant arm than the control arm. We've shown that in NIAGARA and other trials before. These drugs don't seem to compromise the ability to perform surgery. It's also true in the enfortumab vedotin-related adverse events. The skin toxicity was as expected because that happens in the first 3 cycles. But the peripheral neuropathy, which escalates with increasing numbers of cycles, was modest compared to other studies which we've performed in this setting.

Thomas PowlesProfessor

I think it is very fair to say that this is a positive and clinically meaningful study for event-free survival, but really importantly for overall survival. It is amazing that enfortumab vedotin is so effective in this disease. It does not seem to matter with which ADC you combine the drugs, and we have shown you can give very short periods of therapy and get excellent results, benefits across subgroups, and the safety profile, attractive and patient-centric. So, I think it does support this as a new potential standard of care. As I said before, I am so lucky to be involved in a journey where we are curing what was a really common and really nasty cancer, and it is not quite complete, but this is an important step on that journey. Many thanks for your attention.

Dave FredricksonEVP of Oncology Business

Okay, we have 5 minutes or so for questions for Professor Powles. Do we have a microphone that will move down? Yours, table 1 here in the front was very fast with hands up.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day